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The reduction or loss of plakoglobin expression in late-stage bladder cancer has been correlated with poor survival where
upregulation of this catenin member by histone deacetylase inhibitors has been shown to accompany tumour suppression in an in vivo
model. In this study, we directly addressed the question of the role of plakoglobin in bladder tumorigenesis following restoration, or
knockdown of expression in bladder carcinoma cell lines. Restoration of plakoglobin expression resulted in a reduction in migration
and suppression of tumorigenic potential in vivo. Immunocytochemistry revealed cytoplasmic and membranous localisation of
plakoglobin in transfectants with o1% of cells displaying detectable nuclear localisation of plakoglobin. siRNA knockdown
experiments targeting plakoglobin, revealed enhanced migration in all cell lines in the presence and absence of E-cadherin expression.
In bladder cell lines expressing low levels of plakoglobin and desmoglein-2, elevated levels of desmoglein-2 were detected following
restoration of plakoglobin expression in transfected cell lines. Analysis of wnt signalling revealed no activation event associated with
plakoglobin expression in the bladder model. These results show that plakoglobin acts as a tumour suppressor gene in bladder
carcinoma cells and the silencing of plakoglobin gene expression in late-stage bladder cancer is a primary event in tumour progression.
British Journal of Cancer (2005) 92, 2153–2159. doi:10.1038/sj.bjc.6602651 www.bjcancer.com
Published online 7 June 2005
& 2005 Cancer Research UK
Keywords: plakoglobin; bladder cancer; desmosome; signalling
                                             
Loss or altered expression of cadherin or catenins in neoplastic
progression has been a frequent finding in a variety of human
cancers (Gee et al, 1998; Bukholm et al, 2000; Bussemakers et al,
2000; Hajra and Fearon, 2002), where altered E-cadherin expres-
sion has featured most commonly as an indicator of poor
prognosis in bladder cancer (Shimazui et al, 1996; Mialhe et al,
1997; Shariat et al, 2001). Loss of expression of the invasive
suppressor gene E-cadherin in bladder carcinoma cell lines has
been associated with novel expression of the invasive promoter
gene N-cadherin (Gee et al, 1998). Downregulation of plakoglobin
accompanies such events in bladder tumorigenesis although we do
not know whether changes in plakoglobin expression contribute
to tumour progression. Recently, we have shown that exposure of
late-stage bladder carcinoma cells to histone deacetylase inhibitors
upregulates plakoglobin expression and suppresses the tumori-
genic potential (Canes et al, 2005). However, from these
experiments we cannot assess the contribution of plakoglobin to
tumour suppression since multiple genes are modulated following
exposure to this class of agent.
Numerous studies report that altered expression of individual
catenins is correlated to prognosis (Shimazui et al, 1996; Mialhe
et al, 1997; Morita et al, 1999) with alterations in plakoglobin
expression linked to clinical outcome in different tumour types
(Pantel et al, 1998; Amitay et al, 2001; Papergerakis et al, 2004).
In bladder cancer, loss or reduced plakoglobin expression has
been correlated with poor survival (Shimazui et al, 1996; Syrigos
et al, 1998). Despite the growing number of correlative studies, the
possible role or mechanism by which each individual member of
the cadherin–catenin complex may contribute to neoplastic
progression is not fully understood.
Plakoglobin, also referred to as g-catenin, is a structural and
functional homolog of b-catenin and Armadillo, both of which
serve adhesion and signalling roles in development (Ben-Ze’ev and
Geiger, 1998; Bierkamp et al, 1999; Kolligs et al, 2000). However,
plakoglobin differs from b-catenin by interaction with the desmo-
somal cadherins (Marcozzi et al, 1998; Bierkamp et al, 1999) where
it is an indispensable structural element of the desmosome.
Increased b-catenin levels have been shown to result in b-
catenin binding to transcription factors of the Tcf/Lef family
accompanied by increased tumorigenicity, indicating that b-
catenin has oncogenic potential (Peifer, 1997). In contrast, several
groups have reported that plakoglobin acts as a tumour suppressor
gene. This was initially inferred from studies showing loss of
heterozygosity of the plakoglobin gene in certain types of tumours
(Aberle et al, 1995), reduced plakoglobin expression in different
tumour types (Sommers et al, 1994; Pantel et al, 1998; Syrigos et al,
1998) and the demonstration that plakoglobin overexpression can
suppress the tumorigenicity of mouse and human cells (Simcha
et al, 1996). Recently, however, several reports have suggested that
plakoglobin can have oncogenic properties in specific tissues. This
hypothesis originated from the observation that plakoglobin
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sexpression correlated positively with the grade of hepatocellular
carcinomas, being the highest in poorly differentiated tumors. A
positive correlation was also found between elevated expression of
plakoglobin and vascular invasion (Endo et al, 2000). More direct
evidence was presented by Kolligs et al (2000), who demonstrated
that overexpression of wild-type plakoglobin elicits neoplastic
transformation in a rat kidney epithelial cell line.
In this study we report restoration of plakoglobin expression
in late-stage bladder carcinoma cells suppresses migration and
in vivo tumorigenicity. In the bladder carcinoma model, where
downregulation of plakoglobin appears to accompany loss of E-




Human bladder cell line RT4, EJ, 5637, RT112, HT1376,
HU456, KK47, UM-UC-3, SCaBER, J82, T24, TCCSUP, MGHU1,
CUBIII, PSI, HT1197 (ATCC) and BC16 (kindly provided by
Dr C Reznikoff, University of Wisconsin) were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with
7.5% foetal bovine serum and penicillin/streptomycin.
Transfection
EJ and J82 bladder carcinoma cell lines were plated at 3 10
5cells
per 60mm dish 24h before lipofection. The plakoglobin consruct
(generous gift from Dr Ben-Ze’ev) or the neomycin resistance gene
was introduced into cells using the lipofectin reagent (Gibco BRL,
Gaithersburg, MD, USA) Following incubation, cells were washed
and maintained in standard medium. At 48h post-transfection,
cells were split into neomycin containing medium to select for
successfully transfected colonies. Individual colonies screened for
drug selection were ring-cloned 2 weeks later.
Antibodies
The following antibodies were used in the study: N-cadherin clone
13A9 (1:200 kindly provided by Dr M Wheelock, Eppley Cancer
Center, WI, USA), plakoglobin (1:1000), b-catenin (1:1000),
(Transduction Laboratories, Lexington, KY, USA), E-cadherin
(1:500 Zymed Laboratories, South San Francisco, CA, USA) and
b-actin (1:1000 Sigma, St Louis, MD, USA).
Western blot analysis
Subconfluent dishes of cells were washed in phosphate-buffered
saline (PBS) followed by lysis in hot sample buffer (0.08 M Tris,
pH 6.8; 0.07 M SDS, 10% glycerol, 0.001% bromophenol blue and
1m M CaCl2) and sheared through a 26-gauge needle. Lysates were
then assayed for protein concentration using the BSA method
(Pierce, Rockford, IL, USA). After determination of protein
content, b-mercaptoethanol (1%) was added to each sample.
Samples were boiled for 5min and protein was loaded in each lane
of a 7.5% polyacrylamide gel. Proteins were transferred overnight
onto nitrocellulose. Membranes were blocked in 10% milk in TBS
with 0.05% Tween (TBST) and placed on primary antibody
overnight at 41C. Blots were washed in TBST, three times for
15min each, and secondary antibody linked to horseradish
peroxidase was incubated with the blots for 60min at room
temperature. Blots were then washed as described above and
developed with an ECL kit (Amersham, Arlington Heights, IL,
USA).
siRNA transfection
The siRNA target sequence AGTCGGCCATTGTGCATCT (start –
nucleotide 490, Dharmacon siDesign Center, Dharmacon RNA
Technologies, Lafayette, CO, USA) was selected based on a lack
of homology with other catenin members and localisation at the
50 end of the gene. Target cells were seeded at 4 10
4cells per well
in a 24-well plate in media containing 10% foetal bovine serum.
Transfection of the RNA oligonucleotide and a scrambled control
sequence was performed using Oligofectamine (Invitrogen,
Carlsbad, CA, USA) to result in a final RNA concentration of
200nM. The cells were harvested 48h post-transfection and used
for either Western blot analysis or migration assays.
Migration and invasion assays
In vitro cell migration and invasion assays were carried out using
modified Boyden chambers consisting of Transwell (Corning
Costar Corp., Cambridge, MA, USA) membrane filter inserts (pore
size 8mm) in 24-well tissue culture plates. For migration assays,
fibronectin (20ugml
 1) was used as the chemoattractant. For
invasion assays the upper surfaces of the membranes were coated
with Matrigel (Collaborative Biomedical Products, Bedford, MA,
USA) and placed into 24-well tissue culture plates containing
600ml of NIH/3T3 conditioned media (experimental) or plain
DMEM (control). In both assays, cells (1 10
5) were added to each
Transwell chamber and allowed to invade toward the underside of
the membrane for 8 (J82) or 16h (EJ) at 371C. Cells that passed
through the membrane were fixed in methanol, stained with crystal
violet and counted under a light microscope. Statistical analysis
was performed by a Student’s t-test, where Po0.05 was considered
significant.
Growth in Agar
Agar was made by combining one part 0.9% agarose in DMEM
with two parts DMEM/20% foetal calf serum. A measure of 3ml
aliquots were plated into 60mm bacteriologic dishes and allowed
to gel. Agar top layer was made by combining one part 1.5%
agarose in DMEM with two parts DMEM/12% foetal calf serum
and sufficient cells to achieve a final concentration of either
1 10
5 or 5 10
5 cells per 60mm dish. After solutions had solidi-
fied at room temperature, dishes were returned to the incubator
and fed biweekly by the addition of 1.5ml of agar top.
Tumorigenicity assays
Subconfluent dishes of tranfectant and parental cell lines were
harvested, washed in PBS followed by subcutaneous inoculation
into nu/nu mice (1 10
6cellsinoculum
 1) using a 26-gauge
needle. Weekly checks for tumour growth and animal health
status were performed. Tumours were measured using calipers and
tumour volume was calculated using the following formula:
tumour volume¼length width height p/6. Animal experi-
ments were carried out under the regulations set by the
Institutional Animal Care and Use Committee guidelines.
Immunocytochemistry
Cells were grown on glass slides, washed with PBS and fixed in
3.7% formaldehyde for 15min at room temperature. Cells were
then rinsed in three changes of PBS and permeabilised in 0.5%
Triton X-100 in PBS. Following three washes in PBS, cells were
stained for plakoglobin (Transduction Laboratories, Lexington,
KY, USA) using an automated immunohistochemical processor
(Model 320; Ventana Medical Systems, Tucson, AZ, USA).
Plakoglobin acts as a tumour suppressor gene in bladder cancer
KM Rieger-Christ et al
2154


























Cells were transfected with either 0.8mg TOPFLASH or FOPFLASH,
0.4mg b-Gal and 0.8mg control, b-catenin or plakoglobin plasmid.
Cells were harvested 48h post-transfection and luciferase and
b-Gal activity were measured. Results were scored as luciferase
activity normalised to b-Gal activity.
RESULTS
Cadherin and plakoglobin expression in bladder
carcinoma cell lines
The expression profile of classic cadherins within a series of
bladder carcinoma cell lines has been described (Gee et al, 1998).
Figure 1 shows total cell lysates from a representative bladder
carcinoma cell panel probed in Western blot analysis. This panel
includes bladder cell lines expressing E-cadherin in the absence
of N-cadherin, E-cadherin in the presence of N-cadherin and
N-cadherin in the absence of E-cadherin. It is of note that, with
the exception of KK47, cell lines lacking E-cadherin expression
display minimal plakoglobin expression. These results are similar
to observations made in other human carcinoma cell lines
(Bussemakers et al, 2000; Winn et al, 2002) and suggest a link
between the presence of E-cadherin and the level of plakoglobin
expression.
Establishment and characterisation of plakoglobin
transfectants
Late-stage events in bladder tumorigenesis include loss of E-
cadherin expression and downregulation of plakoglobin. Although
it has been shown that E-cadherin is an invasive suppression gene,
it is not known whether the reduction in plakoglobin expression
observed in these carcinoma cells has a primary or secondary role
to play in tumour progression. To address this question we
selected representative bladder cell lines that lack E-cadherin and
have low plakoglobin expression levels (EJ and J82) as recipients in
transfection. In each case, our goal was to restore plakoglobin
expression to levels recorded in earlier stages of tumour
progression. Restoration of plakoglobin expression in bladder cell
lines EJ and J82 was achieved following lipofection and confirmed
in Western blot analysis (Figure 2). Three EJ and J82 clones were
selected following limiting dilution, identified as expressing levels
of plakoglobin comparable to that recorded in E-cadherin cell lines
(Figure 1). In EJ and J82 cell lines, the level of N-cadherin
expression was increased in plakoglobin transfectants as compared
to neomycin controls. Immunocytochemical evaluation of each
clone revealed cytoplasmic and membranous localisation of
plakoglobin (Figure 3) with o1% of cells displaying nuclear
localisation of plakoglobin. No difference in growth rate was
recorded between EJ and J82 cells overexpressing plakoglobin and
neomycin control transfectants. The cloning efficiency of the EJ
control and plakoglobin transfectants in soft agar was 2871.5 and
1171%, respectively. The bladder cell line J82 and the plakoglobin
transfectants did not form colonies in this assay.
Migration and invasion assays
We initially evaluated the effect of forced plakoglobin expression
on the invasion and migration potential of transfected cells. Using
standard in vitro assays, EJ and J82 plakoglobin transfectants were
tested in migration assays. Figure 4 shows results from a
representative assay demonstrating a significant reduction in
migration in both EJ and J82 plakoglobin transfectants. Using the
same cell lines in invasion assays, no significant change in the
invasive capacity of the cells was detected in repeated assays
(Figure 4).
Downregulation of plakoglobin using siRNA
If plakoglobin has a role to play in cell migration, downregulation
of this catenin should promote migrational activity in bladder
carcinoma cells. Figure 5 shows a Western blot analysis of siRNA
experimental and control transfectants demonstrating downregu-
lation of plakoglobin in EJ and J82 cells transfected with
plakoglobin siRNA. Figure 6 shows enhanced migration of both
cell lines following downregulation of plakoglobin expression, a
result consistent with and reciprocal to, the inhibition of migration
recorded following restoration of plakoglobin expression. Harvest-
ing parallel cultures of transfectants at the end of the migration
assay revealed continued downregulation of plakoglobin at the 72-
h time point.
To address the question as to whether reduction of plakoglobin
expression would alter migration in bladder carcinoma cells
expressing E-cadherin, we performed the same experiment on
CUBIII and HU456 bladder carcinoma cell lines that express E-
cadherin. siRNA knockdown of plakoglobin increased the
migratory potential in both CUBIII and HU456 cells by
145.978.4 and 185.2722%, respectively.
Tumorigenic potential of plakoglobin transfectants
Parental cell line J82 is nontumorigenic when implanted sub-
cutaneously into nude mice. At 6 weeks, no tumour formation was
recorded in the three J82 plakoglobin transfectants tested in vivo (0
out of 12). After the same time period EJ neo-transfectants
produced large tumours at 11 out of 12 sites with EJ plakoglobin
transfectants generating tumours in three out of 12 sites. Tumours
arising from EJ neo-controls recorded average tumour volumes
45 times that recorded for EJ plakoglobin transfectant tumours.
E-cadherin
N-cadherin
12 345 678 9 1 0 1 1 1 2
Plakoglobin
-Actin
Figure 1 Western blot analysis showing endogenous levels of E-
cadherin, N-cadherin, plakoglobin and b-actin expression in a representa-
tive panel of bladder carcinoma cell lines. Lane 1, RT4; lane 2, EJ; lane 3,
5637, lane 4, RT112; lane 5, HT1376; lane 6, HU456; lane 7, KK47; lane 8,
UM-UC-3; lane 9, SCaBER; lane 10, J82; lane 11, TCCSUP; lane 12, BC16.
Note the cell lines TCCSUP, J82, UM-UC-3 and EJ express N-cadherin in








Figure 2 Western blot analysis showing EJ and J82 transfectants probed
for expression of b-catenin, N-cadherin, plakoglobin and b-actin. Lanes 1–
3 in each panel represent three clones expressing high levels of plakoglobin
following transfection. Lanes 4–6 represent three control clones harboring
the neomycin-resistance gene.
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sRelationship between expression levels of plakoglobin and
desmosomal proteins
Plakoglobin is not only found in the cadherin complex but exists as
an integral component of the desmosomal complex. We examined
the constitutive expression levels of desmocollin-2 and desmoglein-2
in the panel of bladder carcinoma cell lines. Figure 7 shows an
absence or reduced expression of desmocollin-2 and desmoglein-2
expression in cells lines in which plakoglobin levels were low. To
determine the relationship between the levels of desmosomal
proteins and plakoglobin, we analysed the expression levels of
desmoglein-2 in the control and plakoglobin transfectants of each
bladder carcinoma cell recipient. As shown in Figure 8, the
expression levels of desmoglein-2 increased in EJ plakoglobin
transfectants but remained undetected in J82 control and
plakoglobin transfectants (data not shown).
Signalling pathway(s) following forced plakoglobin
expression
APC is reported to regulate both b- and g-catenin where the
oncogenic action of b-catenin is dependent on Tcf/Lef function. In
addition, the oncogenic action of g-catenin in kidney epithelial
Figure 3 Parental cell lines (A) J82 and (B) EJ displayed no detectable staining of plakoglobin in immunohistochemistry. In J82 transfectants (C)
cytoplasmic with limited membranous plakoglobin was observed. Less than 1% of transfectants displayed nuclear localization of plakoglobin. In EJ























































Figure 4 In vitro migration and invasion assay results showing decreased migration of plakoglobin transfectants with no significant alteration in the invasive
capacity as compared to neomycin controls.
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scells was linked to elevated c-myc expression (Kolligs et al, 2000).
We have probed lysates from parental and transfected cells to
establish the levels of c-myc expression and have found no
alteration in the expression level of this nuclear protein in either
EJ or J82 plakoglobin transfectants. We also probed lysates for
MAP kinase and AKT expression and activation, demonstrating
unchanged levels of both in parental and transfected cell lines
(data not shown).
Although b-catenin’s role in wnt signalling has been well
established, the role of plakoglobin in this pathway is less clear. To
determine basal levels of wnt signalling in EJ and J82 cells, we
scored the activation of Tcf/Lef-dependent transcription using
the activity of the TOPFLASH reporter as an end point. Both cell
lines exhibited low levels of wnt activity (data not shown). When
b-catenin was included in the assay J82 showed no significant
wnt activation (Topþb-cat/Top¼1.9), whereas EJ showed a
modest increase (Topþb-cat/Top¼13). Hence, we proceeded to
determine whether plakoglobin would effect wnt signalling in the
EJ cell line. Although plakoglobin decreased TOPFLASH activity
(TopþPK/Top¼0.26), it also affected FOPFLASH (FopþPK/
Fop¼0.52). Since the FOPFLASH reporter contains mutant Tcf/
Lef sites, these results suggest that plakoglobin does not mediate
its effects through the wnt pathway in this model.
DISCUSSION
Plakoglobin has been reported to act both as an oncogene and a
tumour suppressor gene depending on the cell type (Simcha et al,
1996; Kolligs et al, 2000; Winn et al, 2002). Although a role for
plakoglobin in bladder cancer has not been established, reduced
plakoglobin expression has been linked to poor prognosis in
patients with bladder carcinoma (Syrigos et al, 1998).
To directly investigate the role of plakoglobin in bladder
tumorigenesis, we transfected plakoglobin into bladder carcinoma
cells expressing low levels of endogenous protein. Using standard
in vitro migration and invasion assays, we demonstrated inhibition
of migratory potential with no significant alteration recorded in
the invasive capacity of the plakoglobin transfectants.
In reciprocal experiments, where plakoglobin expression was
knocked down using siRNA, we demonstrated enhanced migra-
tion. This was observed in bladder carcinoma cell lines expressing









































Figure 5 siRNA directed against plakoglobin downregulates protein
expression. EJ and J82 cells were transfected with siRNA directed against
plakoglobin or control transfected with a scrambled siRNA. Cells were
lysed 48-h post-transfection and Western blots were probed with anti-
























Figure 6 Migration assay of EJ and J82 cells transfected with plakoglobin
siRNA or control transfected controls harbouring scrambled siRNA
sequence. The cells transfected with siRNA directed against plakoglobin
displayed a statistically significant increase in migration capacity compared
to the mock-transfected controls. Numbers are expressed as percent
control where mock-transfectants were considered 100%.
1 23 4 5 67 8 9 1 2 345 678 9
Desmoglein-2 Desmocollin-2/3
10 11 12 13 14 15 16 17 18 10 11 12 13 14 15 16 17 18
Figure 7 Western blot analysis showing desmocollin-2/3 and desmoglein-2 expression in a panel of bladder carcinoma cell lines. Note that cell lines
expressing reduced levels of plakoglobin (Figure 1) also show reduced expression of desmoglein and desmocollin. Lane 1, EJ; lane 2, 5637; lane 3, J82, lane 4,
TCCSUP; lane 5, T24; lane 6, SCaBER; lane 7, RT112; lane 8, RT4; lane 9, PSI; lane 10, BC16.1; lane 11, CUBIII; lane 12, EJ; lane 13, HT1197; lane 14, HT1376;




12 3 4 56
EJ
Figure 8 Western blot analysis showing total cell lysates from EJ
plakoglobin transfectant clones (lanes 1–3) and neomycin control cell
lysates (lanes 4–6) probed for desmoglein-2, plakoglobin and b-actin.
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scomplex likely compromises its functionality resulting in enhanced
migration. In N-cadherin expressing cells, the reduction in
minimal levels of plakoglobin also promoted migration. These
results suggest that reduced expression of plakoglobin in bladder
tumorigenesis is a significant event contributing to increased cell
migration, one aspect of the invasive phenotype.
The J82 bladder carcinoma cell line was established from a
late-stage tumour and displays no tumorigenic potential following
subcutaneous implantation in nude mice (Masters et al, 1986). The
restoration of plakoglobin expression did not result in the
acquisition of tumorigenic potential in this cell line demonstrating
a lack of oncogenic action of plakoglobin in this model. In
contrast, the EJ cell line is tumorigenic in this in vivo assay, and
forced expression of plakoglobin in transfected cells resulted in
tumour suppression, further supporting the concept that down-
regulation of plakoglobin is a significant event associated with
bladder tumorigenesis.
Plakoglobin not only associates with cadherins but also exists
as an integral part of the desmosome complex. At the intracellular
aspect, desmogleins (Dsg) and desmocollins (Dsc) bind plakoglo-
bin, which in turn binds directly to the N-terminus of desmoplakin
where the latter bridges the desmosomal complex to the
intermediate filaments. Although the different isoforms of Dsg
and Dsc can be found differentially expressed between and within
different tissues, Dsg2 and Dsc2a,b are common to all desmosomal
tissues. In screening a panel of bladder carcinoma cell lines for
expression of these desmosomal components, it is of note that
both proteins are absent or expressed at low levels in invasive cell
lines displaying minimal plakoglobin protein. Indeed, reduced
desmosome formation in invasive bladder tumours has been
reported (Alroy et al, 1981). Restoration of plakoglobin to EJ cells
resulted in increased detection of desmoglein although we did not
determine whether this represents transcriptional upregulation or
reduced turnover of protein possibly complexed with plakoglobin.
Restoration of desmosome formation following introduction of
plakoglobin has been reported in a squamous carcinoma cell line
(Parker et al, 1998) and desmosomal adhesion has been shown to
inhibit invasion (Tselepis et al, 1998). However, the absence of
detectable desmoglein or desmocollin in J82 cells suggests that the
inhibition of migration recorded in J82 plakoglobin transfectants is
not dependent upon plakoglobin interactions with desmosomal
proteins.
The signalling mechanism(s) by which plakoglobin exerts its
tumour suppressor activity in bladder cells remains unclear. In
numerous human cancers, the wnt/b-catenin signalling pathway is
constitutively activated eliciting activation of specific target genes
including c-myc (He et al, 1998; Kolligs et al, 2000). Winn et al,
(2002) showed that re-expression of plakoglobin in non-small-cell
lung carcinoma cell lines reduced Tcf activity. Our results also
showed that restoration of plakoglobin into bladder carcinoma
cells reduced TOPFLASH activity but FOPFLASH activity was also
reduced, suggesting the effect was not a wnt specific event.
Our observations support the work of Thievessen et al (2003),
who demonstrated that the wnt/b-catenin signalling pathway is
inactive and appears to be turned off in urothelial cancers. The
basal wnt activity in both the EJ and J82 cell lines was comparable
to that seen in the urothelial cell lines in the Thievessen study,
suggesting that the wnt pathway was not activated in these lines.
When b-catenin was added to the assay, J82 showed minimal
activation whereas EJ showed a modest increase, which was
comparable to that reported for the bladder cell line SW1710
(Thievessen et al, 2003). The bladder cells we have used in this
study express N-cadherin in the absence of E-cadherin; therefore,
our results support the idea that E-cadherin expression is not the
only factor determining inducibility of wnt signalling in urothelial
cancer.
In keratinocytes, tyrosine phosphorylation of plakoglobin
results in its translocation from the cell membrane to the nucleus
where it binds to nuclear Tcf/Lef (Hu et al, 2003). In addition,
nuclear plakoglobin expression has been detected in renal cell
carcinomas, where it was strongly associated with clear cell type
and high grade (Aaltomaa et al, 2004). In this study, immunohis-
tochemistry revealed the presence of plakoglobin in the cytoplasm
and at the membrane but not in the nucleus of EJ and J82
transfectants. The absence of nuclear plakoglobin in transfectants
may be indicative of a lack of detectable wnt activity in the bladder
model.
We found no significant change in c-myc protein levels
following forced expression of plakoglobin in bladder cell lines
EJ and J82. In addition, we observed no change in the activation
status of MAP kinase or Akt in plakoglobin transfectants even
though activation of Akt has been implicated in bladder cell
invasion. Hence, plakoglobin in bladder carcinoma cells must be
exerting a tumour suppressor role via alternative signalling
pathways from those established in other carcinoma cell models.
In summary, the restoration of plakoglobin expression in N-
cadherin expressing bladder carcinoma cell lines reduced the
migratory capacity of the cells, reduced growth in soft agar and
suppressed the tumorigenic potential of the cells. These results
demonstrate that plakoglobin acts as a tumour suppressor gene in
bladder carcinoma cells and that the silencing of plakoglobin gene
expression is an important event in bladder tumour progression.
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